Stock Analysis of Brickell Biotech Inc (BBI) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BBI
Close 0.900
Change -0.0097 / 1.07 %
Volume 18717.00
Vol Change 16904.00 / 932.38 %
IndustryBiotechnology & Medical Research
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index No Significant Growth
Value Index Good Value
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Brickell Biotech Inc
PE (TTM)

-0.0016

Very Poor
Price / Book

0.0024

Excellent
Price / Sales

0.0103

Excellent
Piotroski F Score

4.0

Indecisive
Market Cap

2587.43 K

Enterprise Value

-24227.57 K

ROA (TTM)

-122.17

Very Poor
ROE (TTM)

-151.03

Very Poor
Net Margin (TTM)

-643.48

Very Poor
Revenue

77.83 %

404000
Net Profit

88.75 %

-39474.00 K
Debt to Equity

0.0028

Excellent
Altman Z Score

-9.89

Very Poor
Quick Ratio

0

Poor
Cash Ratio

5.59

Very Good


Highs/Lows of Brickell Biotech Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.91 1.07 % 1.59 % 0.930.880115-Apr-2415-Apr-24
Two Week0.91 1.07 % 4.60 % 0.930.874115-Apr-2409-Apr-24
One Month0.9084 0.892 % 4.86 % 0.94970.8605-Apr-2425-Mar-24
Three Month0.98 8.13 % 5.82 % 1.010.8629-Jan-2425-Mar-24
Six Months0.99 9.06 % 17.50 % 1.010.7229-Jan-2427-Dec-23
One year0.6349 41.80 % 28.89 % 1.10.449521-Jul-2309-May-23
Two year17.37 94.82 % 32.16 % 12.60.449529-Jun-2209-May-23
Five year365.4 99.75 % 84.16 % 3.580.449517-Aug-2209-May-23
Ten year3780.0 99.98 % 182.08 % 4882.50.449515-Jun-1509-May-23


Technical View of Brickell Biotech Inc
RSI

48.25

Neutral
MACD

-0.0039

Bullish
ADX

11.98

Neutral
Super Trend

0.954

Mild Bearish
Williams %R

-65.34

Neutral
CCI

13.15

Neutral


EMA 5

0.903

Strong Bearish
EMA 15

0.902

Neutral
EMA 50

0.911

Mild Bearish
EMA 100

0.919

Strong Bearish
SMA 100

0.906

Whipsaw
SMA 200

0.825

Mild Bullish
SMA 5 / 20

0.900 / 0.900

Neutral
SMA 15 / 50

0.901 / 0.922

Mild Bearish
SMA 50 / 200

0.922 / 0.825

Mild Bullish




Charts of Brickell Biotech Inc


Returns of Brickell Biotech Inc with Peers
Period / StockBBISRNENOVNAGRXLMDX
1 Week-1.07%-12.43%-44.12%-15.10%0%
1 Mth-0.892%2.86%-77.60%3.76%0%
3 Mth-8.13%-71.33%-92.65%-68.52%-62.44%
6mth-9.06%-78.11%-93.37%-80.12%-92.00%
1 Year41.80%-84.04%-96.63%-92.44%-96.67%
2 Year-94.82%-95.32%-98.88%-99.54%-99.72%
5 Years-99.75%-94.46%-99.64%-99.99%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Brickell Biotech Inc with Peers
Ratio / StockBBISRNENOVNAGRXLMDX
PE-0.0016-0.227-0.068-127.87-0.0176
P/B0.00241.190.409-82.18-0.086
ROA-122.17-113.01-33.40-64.90-79.47
ROE-151.03-990.86-600.9100
Debt To Equity0.0028-1.900.0415-0.127-3.39
Revenue404000
77.83 % 		62839.00 K
18.78 % 		23682.00 K
700.61 % 		19975.00 K
83.53 % 		254476 K
39.62 %
Net Income-39474.00 K
88.75 % 		-572843.00 K
33.74 % 		-31311.00 K
5.45 % 		-13926.00 K
45.20 % 		-449195.00 K
343.81 %


Technicals of Brickell Biotech Inc with Peers
Technical / StockBBISRNENOVNAGRXLMDX-
ADX11.9812.4433.7421.0121.24
CMF-0.2720.0114-0.1190.193-0.608
MFI27.0552.3633.2757.590
RSI48.2541.0524.1045.5223.80
MACD Abv SignalTrueTrueFalseTrueFalse
Price Above 50 MAFalseFalseFalseFalseFalse-
Price Above 200 MATrueFalseFalseFalseFalse-


About : Brickell Biotech Inc

Address : 5777 Central Avenue, Boulder, CO, United States, 80301
Tel : 720 505 4755
URL : https://www.brickellbio.com
Code : BBI, ISIN : US10802T1051, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 15_Mar_1993
Employee Count : 16

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.


Note : All Data Generated at the End of Trading Hours (EOD Data)